• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

赖氨酸氧化酶基因家族成员在骨髓增殖性肿瘤中的表达。

The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.

机构信息

The Hematology Unit, Bnai-Zion Medical Center, Haifa, Israel.

出版信息

Am J Hematol. 2013 May;88(5):355-8. doi: 10.1002/ajh.23409. Epub 2013 Mar 12.

DOI:10.1002/ajh.23409
PMID:23494965
Abstract

Myeloproliferative neoplasms (MPNs) are malignant disorders originating from clonal expansion of a single neoplastic stem cell and characteristically show an increase in bone marrow reticulin fibers. Lysyl oxidases (LOXs) are copper-dependent amine oxidases that play a critical role in the biogenesis of connective tissue by crosslinking extracellular matrix proteins, collagen and elastin. Expression of LOX gene family members is increased in disorders associated with increased fibrosis. To evaluate involvement of LOX gene family in various MPNs. In-situ hybridization was used to detect Lysyl-Oxidase family members in bone marrow biopsies from patients with different MPNs. We compared normal bone marrows and those from patients with polycythemia vera, essential thrombocythemia, chronic myeloid leukemia, and primary myelofibrosis (PMF). Serum levels of lysyl-oxidase from patients with PMF and healthy controls were also examined. LOX gene family was not detected in normal bone marrows. All members of the LOX gene family were over expressed in PMF. In other MPNs a differential pattern of expression was observed. Differences in gene expression were statistically significant (P < 0.010). The medianserum LOX levels in normal controls was 28.4 ± 2.5 ng\ml and 44.6 ± 9.44 ng\ml in PMF (P = 0.02). The varying pattern of expression of LOX genes may reflect differences in the pathophysiology of bone marrow fibrosis in these MPNs. These observations could be used as the basis for future targeted therapy directed against bone marrow fibrosis.

摘要

骨髓增殖性肿瘤(MPN)是起源于单个肿瘤干细胞克隆性扩张的恶性疾病,其特征是骨髓网状纤维增加。赖氨酰氧化酶(LOX)是一种铜依赖性胺氧化酶,通过交联细胞外基质蛋白、胶原蛋白和弹性蛋白,在结缔组织的生物发生中发挥关键作用。LOX 基因家族成员的表达在与纤维化增加相关的疾病中增加。为了评估 LOX 基因家族在各种 MPN 中的参与情况。使用原位杂交技术检测来自不同 MPN 患者的骨髓活检中的赖氨酰氧化酶家族成员。我们比较了正常骨髓和真性红细胞增多症、特发性血小板增多症、慢性髓系白血病和原发性骨髓纤维化(PMF)患者的骨髓。还检查了 PMF 患者和健康对照者的血清赖氨酸氧化酶水平。LOX 基因家族在正常骨髓中未检测到。LOX 基因家族的所有成员在 PMF 中均过度表达。在其他 MPN 中观察到表达的差异模式。基因表达的差异具有统计学意义(P < 0.010)。正常对照组血清 LOX 水平中位数为 28.4 ± 2.5ng/ml,PMF 为 44.6 ± 9.44ng/ml(P = 0.02)。LOX 基因表达的不同模式可能反映了这些 MPN 中骨髓纤维化的病理生理学差异。这些观察结果可以作为针对骨髓纤维化的未来靶向治疗的基础。

相似文献

1
The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.赖氨酸氧化酶基因家族成员在骨髓增殖性肿瘤中的表达。
Am J Hematol. 2013 May;88(5):355-8. doi: 10.1002/ajh.23409. Epub 2013 Mar 12.
2
The role of beta-catenin in chronic myeloproliferative disorders.β-连环蛋白在慢性骨髓增殖性疾病中的作用。
Hum Pathol. 2008 Oct;39(10):1454-8. doi: 10.1016/j.humpath.2008.02.007. Epub 2008 Jul 11.
3
Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.鉴定出孤啡肽作为 JAK2 V617F 依赖性细胞因子产生和骨髓重构的扩增剂在骨髓增殖性肿瘤中的作用。
FASEB J. 2012 Feb;26(2):894-906. doi: 10.1096/fj.11-193078. Epub 2011 Nov 3.
4
Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.骨髓增殖性肿瘤患者血小板和巨核细胞中 Dkk3 蛋白表达增加。
Thromb Haemost. 2011 Jan;105(1):72-80. doi: 10.1160/TH10-03-0172. Epub 2010 Oct 26.
5
Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.慢性骨髓增殖性疾病的发病机制:真性红细胞增多症、原发性血小板增多症、特发性骨髓化生及慢性粒细胞白血病。
Semin Hematol. 1999 Jan;36(1 Suppl 2):3-8.
6
Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.骨髓活检(BMB)。二、骨髓增殖性疾病中的骨髓活检。
Morphol Embryol (Bucur). 1989 Apr-Jun;35(2):117-27.
7
[Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].[骨髓活检在慢性骨髓增殖性疾病中的预后价值]
Recenti Prog Med. 2003 Jul-Aug;94(7-8):314-20.
8
GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.GATA1 在原发性骨髓纤维化的前纤维化和纤维化阶段以及其他骨髓增殖性肿瘤的骨髓纤维化进展中下调。
Leuk Res. 2021 Jan;100:106495. doi: 10.1016/j.leukres.2020.106495. Epub 2020 Dec 15.
9
Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.转化生长因子β-1(TGFβ-1)的异常表达本身并不能区分纤维化与非纤维化的慢性骨髓增殖性疾病。
J Pathol. 2005 Apr;205(5):548-57. doi: 10.1002/path.1744.
10
Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.骨髓基质细胞分泌激活素 A 与骨髓纤维化程度相关:骨髓增生性肿瘤患者骨髓龛的异质性。
Ann Hematol. 2021 Jan;100(1):105-116. doi: 10.1007/s00277-020-04306-w. Epub 2020 Oct 21.

引用本文的文献

1
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape.旧疗法,新问题:在药物治疗背景下重新思考放血疗法。
Pharmaceuticals (Basel). 2025 Aug 16;18(8):1212. doi: 10.3390/ph18081212.
2
Molecular characterization underlying IFN-α2 treatment in polycythemia vera: a transcriptomic overview.真性红细胞增多症中IFN-α2治疗的分子特征:转录组概述
Mol Cell Biochem. 2025 Mar 3. doi: 10.1007/s11010-025-05238-7.
3
Investigational drugs in early phase trials for myelofibrosis.用于骨髓纤维化早期试验的研究性药物。
Expert Opin Investig Drugs. 2024 Dec;33(12):1231-1244. doi: 10.1080/13543784.2024.2434696. Epub 2024 Nov 27.
4
Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications-A Narrative Review.费城阴性骨髓增殖性肿瘤的心血管风险:机制与影响——一篇叙述性综述
Curr Issues Mol Biol. 2024 Aug 2;46(8):8407-8423. doi: 10.3390/cimb46080496.
5
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.骨髓纤维化的分子遗传学特征:对诊断、预后及治疗进展的意义
Cancers (Basel). 2024 Jan 25;16(3):514. doi: 10.3390/cancers16030514.
6
Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.好警察,坏警察:多发性骨髓瘤的免疫景观剖析。
Biomolecules. 2023 Nov 7;13(11):1629. doi: 10.3390/biom13111629.
7
Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.重新审视循环细胞外基质片段作为骨髓纤维化及相关肿瘤的疾病标志物
Cancers (Basel). 2023 Aug 29;15(17):4323. doi: 10.3390/cancers15174323.
8
Proteins: Neglected active ingredients in edible bird's nest.蛋白质:燕窝中被忽视的活性成分。
Chin Herb Med. 2023 May 16;15(3):383-390. doi: 10.1016/j.chmed.2023.02.004. eCollection 2023 Jul.
9
Lysyl oxidase like-2 in fibrosis and cardiovascular disease.赖氨酰氧化酶样蛋白 2 在纤维化和心血管疾病中的作用。
Am J Physiol Cell Physiol. 2023 Sep 1;325(3):C694-C707. doi: 10.1152/ajpcell.00176.2023. Epub 2023 Jul 17.
10
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.赖氨酸氧化酶抑制物与 5-氮杂胞苷协同作用恢复骨髓增生异常和髓系恶性肿瘤中的红细胞生成。
Nat Commun. 2023 Mar 17;14(1):1497. doi: 10.1038/s41467-023-37175-8.